Voyageur Pharmaceuticals Ltd. is dedicated to extracting active pharmaceutical ingredients (APIs) from various mineral resources. The firm's strategic objectives include manufacturing radiocontrast compounds derived from barium and iodine, in addition to developing pharmaceuticals that incorporate bromine. The company boasts complete ownership of three barium sulfate deposits in British Columbia, Canada, with two sites offering material suitable for the pharmaceutical barite industry. Furthermore, Voyageur holds stakes in a rich brine project in Utah, USA, which contains high concentrations of iodine, lithium, and bromine. The entity, which was previously named Voyageur Minerals Ltd., adopted its current moniker, Voyageur Pharmaceuticals Ltd., in December 2019. Headquartered in Calgary, Canada, the company operates from this location.
—
Voyageur Pharmaceuticals Ltd. is dedicated to extracting active pharmaceutical ingredients (APIs) from various mineral resources. The firm's strategic objectives include manufacturing radiocontrast compounds derived from barium and iodine, in addition to developing pharmaceuticals that incorporate bromine. The company boasts complete ownership of three barium sulfate deposits in British Columbia, Canada, with two sites offering material suitable for the pharmaceutical barite industry. Furthermore, Voyageur holds stakes in a rich brine project in Utah, USA, which contains high concentrations of iodine, lithium, and bromine. The entity, which was previously named Voyageur Minerals Ltd., adopted its current moniker, Voyageur Pharmaceuticals Ltd., in December 2019. Headquartered in Calgary, Canada, the company operates from this location.
—
Daily adjusted close
Voyageur Pharmaceuticals Ltd. is dedicated to extracting active pharmaceutical ingredients (APIs) from various mineral resources. The firm's strategic objectives include manufacturing radiocontrast compounds derived from barium and iodine, in addition to developing pharmaceuticals that incorporate bromine. The company boasts complete ownership of three barium sulfate deposits in British Columbia, Canada, with two sites offering material suitable for the pharmaceutical barite industry. Furthermore, Voyageur holds stakes in a rich brine project in Utah, USA, which contains high concentrations of iodine, lithium, and bromine. The entity, which was previously named Voyageur Minerals Ltd., adopted its current moniker, Voyageur Pharmaceuticals Ltd., in December 2019. Headquartered in Calgary, Canada, the company operates from this location.